Helen & Robert Appel Alzheimer’s Disease Research Institute

Publications

Found 424 results
[ Author(Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
Dodart J-C, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM.  2005.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 102(4):1211-6.
Dodart J-C, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM et al..  2002.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.. Nat Neurosci. 5(5):452-7.
Diao J, Burré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Südhof TC, Brunger AT.  2013.  Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2.. Elife. 2:e00592.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.  2002.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.. Science. 295(5563):2264-7.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM.  2001.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 98(15):8850-5.
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'dell MA, Taylor JW, Harmony JAK, Aronow BJ, Bales KR, Paul SM et al..  2004.  ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.. Neuron. 41(2):193-202.
DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM.  2002.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 99(16):10843-8.
de Haas R, Heltzel LCMW, Tax D, van den Broek P, Steenbreker H, Verheij MMM, Russel FGM, Orr AL, Nakamura K, Smeitink JAM.  2019.  To be or not to be pink(1): contradictory findings in an animal model for Parkinson's disease.. Brain Commun. 1(1):fcz016.
Davies CW, Chaney J, Korbel G, Ringe D, Petsko GA, Ploegh H, Das C.  2012.  The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).. Bioorg Med Chem Lett. 22(12):3900-4.
Das C, Hoang QQ, Kreinbring CA, Luchansky SJ, Meray RK, Ray SS, Lansbury PT, Ringe D, Petsko GA.  2006.  Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.. Proc Natl Acad Sci U S A. 103(12):4675-80.
Das M, Mao W, Voskobiynyk Y, Necula D, Lew I, Petersen C, Zahn A, Yu G-Q, Yu X, Smith N et al..  2023.  Alzheimer risk-increasing TREM2 variant causes aberrant cortical synapse density and promotes network hyperexcitability in mouse models.. Neurobiol Dis. 186:106263.
C
Clelland CDudley, Fan L, Saloner R, Etchegaray JIker, Altobelli CRichard, Salomonsson S, Maltos AM, Sachdev A, Zhu J, Lee S-I et al..  2025.  Opposing role of phagocytic receptors MERTK and AXL in Progranulin deficient FTD.. Commun Biol. 8(1):971.
Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P et al..  2011.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.. Nature. 469(7328):47-52.
Cirrito JR, Yamada KA, Finn MBeth, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM.  2005.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.. Neuron. 48(6):913-22.
Choi DW, Armitage R, Brady LS, Coetzee T, Fisher W, Hyman S, Pande A, Paul S, Potter W, Roin B et al..  2014.  Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.. Neuron. 84(3):554-63.
Cho S-H, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, Ransohoff RM, Gan L.  2011.  CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease.. J Biol Chem. 286(37):32713-22.
Cho S-H, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, Krabbe G, Sohn PDongmin, Lo I, Minami S et al..  2015.  SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β.. J Neurosci. 35(2):807-18.
Cheng F, Wang F, Tang J, Zhou Y, Fu Z, Zhang P, Haines JL, Leverenz JB, Gan L, Hu J et al..  2024.  Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease.. Cell Rep Med. 5(2):101379.
Chen X, Gan L.  2019.  An exercise-induced messenger boosts memory in Alzheimer's disease.. Nat Med. 25(1):20-21.
Chen H, Fan L, Guo Q, Wong MYing, Yu F, Foxe N, Wang W, Nessim A, Carling G, Liu B et al..  2023.  DAP12 deficiency alters microglia-oligodendrocyte communication and enhances resilience against tau toxicity.. Res Sq.
Chen TN, Orr AL, Orr AG, Vacanti NM.  2025.  Identifying Links between Alzheimer's Disease and Type 2 Diabetes through Proteomics.. J Proteome Res. 24(8):3733-3740.
Chen J, Zhou Y, Mueller-Steiner S, Chen L-F, Kwon H, Yi S, Mucke L, Gan L.  2005.  SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling.. J Biol Chem. 280(48):40364-74.
Chen X, Li Y, Wang C, Tang Y, Mok S-A, Tsai RM, Rojas JC, Karydas A, Miller BL, Boxer AL et al..  2020.  Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy.. Mol Neurodegener. 15(1):2.
Chaudry O, Ndukwe K, Xie L, Figueiredo-Pereira M, Serrano P, Rockwell P.  2022.  Females exhibit higher GluA2 levels and outperform males in active place avoidance despite increased amyloid plaques in TgF344-Alzheimer's rats.. Sci Rep. 12(1):19129.
Chadman KK, Gong S, Scattoni ML, Boltuck SE, Gandhy SU, Heintz N, Crawley JN.  2008.  Minimal aberrant behavioral phenotypes of neuroligin-3 R451C knockin mice.. Autism Res. 1(3):147-58.